1 to 10 of 385
Sort by

Library Entry
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. The authors conclude that MEDI0680 induced peripheral T-cell proliferation and...

Library Entry
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune related enterocolitis (irEC) is among the most common severe irAEs leading to the...

Library Entry
Immunogenicity of pembrolizumab in patients with advanced tumors

Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clearance...

Library Entry
A case of checkpoint inhibitor-induced celiac disease

Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activation. As treatment with ICIs is becoming more common, rare irAEs are also being...

SITC Webinar: I-O Highlights from ASCO 2019

On Aug. 28, 2019, at Noon EDT, please join leading experts for a presentation of the latest advances in cancer immunotherapy emerging from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to register now ! The webinar will summarize key studies on the...

 08-28-2019 | 12:00 - 13:00 ET

Web Page
2019 WIN Leadership Institute

The Society for Immunotherapy of Cancer (SITC) is excited to announce the participants of the inaugural SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute, scheduled for Aug. 19-20, 2019, in Seattle, Wash. Kristin G. Anderson, PhD, Fred Hutchinson Cancer Research...

Library Entry
Advances in Cancer Immunotherapy™ Webinar Series: Updates from the Field: Clinical Updates from SITC 2018 - Recorded Webinar and Presentation Slides

With cutting-edge data regularly emerging from conferences and new FDA approvals, keeping updated with the latest cancer immunotherapy research is an arduous task for a practicing clinician. To complement and expand upon the live Advances in Cancer Immunotherapy™ (ACI) programs, SITC is proud to...

2 attachments